PROTAC enabled avenues for nasopharyngeal carcinoma (NPC) immunotherapy

PROTAC 为鼻咽癌 (NPC) 免疫治疗提供了途径

• 批准号: 2601028
• 金额: --
• 依托单位: Durham University
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2601028
• 关键词: PROTAC; enabled; avenues; nasopharyngeal; carcinoma

Nasopharyngeal carcinoma (NPC) is a type of cancer that affects the lining of the throat. In most cases, NPC presents at a late stage and survival is poor. Current treatments are limited to chemo-and radio-therapy and are associated with significant morbidity and poor quality of life. NPC is always driven by Epstein-Barr virus (EBV) infection and this is an attractive immunotherapeutic target. Epstein-Barr nuclear antigen 1 (EBNA1), an EBV protein, is essential for the survival of infected cells. This project will develop an entirely new class of molecules that target EBNA1 and can be used for NPC immunotherapy - enabling the bodies own immune system to fight the cancer.

鼻咽癌 (NPC) 是一种影响咽喉内壁的癌症。大多数情况下，鼻咽癌已处于晚期，生存率很低。目前的治疗仅限于化疗和放疗，并且与显着的发病率和较差的生活质量相关。鼻咽癌总是由 Epstein-Barr 病毒 (EBV) 感染引起，这是一个有吸引力的免疫治疗靶点。 Epstein-Barr 核抗原 1 (EBNA1) 是一种 EBV 蛋白，对于受感染细胞的生存至关重要。该项目将开发一类全新的分子，以 EBNA1 为靶点，可用于 NPC 免疫治疗——使人体自身的免疫系统能够对抗癌症。